Azilect is the brand name for rasagiline, a Parkinson’s disease medicine developed through work by Technion researchers John Finberg and Moussa Youdim with Teva. The FDA approved the drug in 2006. In the later ADAGIO study, the trial’s prespecified criteria for a possible disease-modifying effect were met at 1 mg daily but not at 2 mg.
Technion research moved into drug development
Finberg and Youdim worked on rasagiline at the Technion’s Rappaport Faculty of Medicine and collaborated with Teva on its development. The Technion’s account describes the researchers’ work and the drug’s route from research to treatment. Its history of rasagiline and Azilect explains the collaboration; the Technion technology-transfer foundation describes how academic research connects with industry.
A drug candidate must pass clinical trials and regulatory review before it can be marketed. FDA approval made rasagiline a treatment for Parkinson’s disease; it did not establish that the drug cures the disease.
What ADAGIO measured
Published in 2009, ADAGIO was an 18-month, double-blind, placebo-controlled delayed-start trial involving 1,176 people with untreated Parkinson’s disease. Participants received rasagiline at 1 mg or 2 mg daily from the start, or placebo for 36 weeks followed by rasagiline for the remaining 36 weeks. The study tested whether early treatment met three prespecified criteria: slower worsening during the first phase, no catch-up after the delayed-start group began treatment, and a difference between groups at the end.
The ADAGIO trial report in the New England Journal of Medicine reported that all three criteria were met for 1 mg daily. For 2 mg, early treatment slowed the measured worsening in the first phase, but the full set of criteria was not met. The results therefore differed by dose; the study did not establish a dose-independent claim that rasagiline slows Parkinson’s disease progression. For a second Israeli university research example, see Copaxone’s development from Weizmann research.